Understanding and overcoming resistance to PARP inhibitors in prostate cancer
Ovcoming PARP Inhibitor Resistance
This study is looking into why some men with advanced prostate cancer don’t benefit from a type of treatment called PARP inhibitors, and it focuses on a protein called NSD3S that might be causing this issue, with the hope of finding better ways to help those patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11043811 on NIH RePORTER |
What this research studies
This research investigates why some prostate cancer patients do not respond to PARP inhibitors, which are used to treat advanced forms of the disease. The team will explore the role of a specific protein, NSD3S, that appears to contribute to this resistance. By studying how NSD3S affects DNA replication in cancer cells, the researchers aim to identify new strategies to enhance the effectiveness of PARP inhibitors. This work could lead to improved treatment options for patients whose cancer has become resistant to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men with advanced prostate cancer, particularly those who have developed resistance to PARP inhibitors or have homologous recombination deficiency.
Not a fit: Patients with early-stage prostate cancer or those who have not been treated with PARP inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer patients who currently do not respond to PARP inhibitors.
How similar studies have performed: Previous research has shown promising results in understanding resistance mechanisms in cancer therapies, suggesting that this approach could yield valuable insights.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lou, Zhenkun — Mayo Clinic Rochester
- Study coordinator: Lou, Zhenkun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.